Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: INSP stock price vs DXC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DXC's multiple
Needs DXC P/E.
Implied fair value · at INSP's multiple
Needs INSP P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INSP FY 2025 (ended Dec 31, 2025) · DXC FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 1.78x · EV / EBITDA 24.73x
Capital structure 38% equity / 62% debt · EV / Revenue 0.25x · EV / EBITDA 1.68x
DXC carries the larger enterprise value at $3.16B against $1.63B; DXC trades on the lower EV / Revenue multiple (0.25x vs 1.78x); DXC on the lower EV / EBITDA (1.68x vs 24.73x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Inspire Medical Systems, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
DXC TECHNOLOGY COMPANY · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.14x
1.03x
Net debt / EBITDA
Leverage against operating earnings
-2.98x
0.69x
Cash and equivalents
Liquid reserves on the balance sheet
$308.27M
$1.74B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BOSTON SCIENTIFIC CORP
INSP vs BSX
Medtronic plc
INSP vs MDT
ABBOTT LABORATORIES
INSP vs ABT
JOHNSON & JOHNSON
INSP vs JNJ
LivaNova PLC
INSP vs LIVN
Accenture plc
INSP vs ACN
INTERNATIONAL BUSINESS MACHINES CORP
INSP vs IBM
COGNIZANT TECHNOLOGY SOLUTIONS CORP
INSP vs CTSH
EPAM Systems, Inc.
INSP vs EPAM
Genpact LTD
INSP vs G
UNISYS CORP
INSP vs UIS
$112.36M
$3.03B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
